Illumina Reports Financial Results for Third Quarter of Fiscal Year 2020

SAN DIEGO–(BUSINESS WIRE)—- $ILMN #ILMN–Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the third quarter of fiscal year 2020. Third quarter 2020 results reflect strong sequential growth: Revenue of $794 million, an increase of 26% compared to the second quarter of 2020 and a 12% decrease compared to $907 million in the prior... Read more

Tampa General Hospital and GE Healthcare's CareComm Saves $40 Million, Cuts 20,000 Excess Days and Reduces Length of Stay

Tampa, FL – October 29, 2020 – Tampa General Hospital (TGH), in partnership with GE Healthcare, reports a $40M reduction of system-wide inefficiencies since launching their CareComm command center with GE’s Command Center Software last August.  Utilizing 20 artificial intelligence applications (aka Tiles), CareComm helps to optimize minute-to-minute patient care operations with real-time actionable information used in CareComm... Read more

Tampa General Hospital and GE Healthcare's CareComm Saves $40 Million, Cuts 20,000 Excess Days and Reduces Length of Stay

Tampa, FL – October 29, 2020 – Tampa General Hospital (TGH), in partnership with GE Healthcare, reports a $40M reduction of system-wide inefficiencies since launching their CareComm command center with GE’s Command Center Software last August.  Utilizing 20 artificial intelligence applications (aka https://www.ge.com/news/press-releases/tampa-general-hospital-and-ge-healthcares-carecomm-saves-40-million-cuts-20000 Read more

Roche’s Tecentriq in combination with Avastin approved in China for people with the most common form of liver cancer

Tecentriq in combination with Avastin is the first and only cancer immunotherapy regimen approved for the treatment of unresectable hepatocellular carcinoma (HCC), the most common form of liver cancer The Tecentriq combination improved overall survival and progression-free survival compared with sorafenib in people with unresectable HCC Approval by the China National Medical Products Administration brings... Read more

PerkinElmer Announces Financial Results for the Third Quarter of 2020

Revenue of $964.0 million; 36% reported growth; 34% organic growth GAAP EPS from continuing operations of $1.57; Adjusted EPS of $2.09 WALTHAM, Mass.–(BUSINESS WIRE)–Oct. 28, 2020– PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today reported financial results for the third quarter ended October 4, 2020. The Company reported... Read more

QIAGEN launches QIAseq Human Exome TR Insights, a new integrated solution for Whole Exome Sequencing

Hilden, Germany, and Germantown, Maryland, October 28, 2020 – QIAGEN today announced the launch of QIAseq Human Exome TR Insights, an innovative solution combining high-performance chemistry with robust bioinformatics to enable customers to sequence and analyze multiple types of genomic variation across the entire human exome. This integrated research solution offers rapid preparation of next-generation... Read more